Sand Grove Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Sand Grove Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-80,821	Closed	-$17.9M	–	21
2025 Q4	$17.9M	Buy	+80,821	New	+$13.1M	6.05%	11

Sand Grove Capital Management's CDTX Position: Q1 2026 in Review

Sand Grove Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 80,821 shares — an estimated $17.9M sold.

Sand Grove Capital Management first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $17.9M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Sand Grove Capital Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Sand Grove Capital Management sold 80,821 Cidara Therapeutics shares in Q1 2026, an estimated $17.9M.
Sand Grove Capital Management first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Sand Grove Capital Management's Cidara Therapeutics position peaked at $17.9M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Sand Grove Capital Management's 13F filing for Q1 2026, filed 15 May 2026.